INC. AND SUBSIDIARIES
TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
Organization and Business Overview
– BioTime, Inc. (“BioTime” or the “Company”) is a clinical-stage biotechnology company targeting
degenerative diseases. BioTime’s programs are based on two proprietary core technology platforms: cell replacement and cell/drug
delivery. With the cell replacement platform, BioTime is producing new cells and tissues with its pluripotent and progenitor cell
technologies. These cells and tissues are developed to replace those that are either rendered dysfunctional or lost due to degenerative
diseases or injuries. BioTime’s cell/drug delivery programs are based upon its proprietary HyStem®
cell and drug delivery matrix technology. HyStem® was designed to provide for the transfer, retention, and/or
engraftment of cell replacement therapies and to act as a device for localized drug delivery.
lead cell replacement clinical product is OpRegen®, a retinal pigmented epithelium (RPE) cell replacement
therapy, which is in a Phase I/IIa multicenter trial for the treatment of late-stage, dry age-related macular degeneration (dry-AMD).
There are currently no FDA-approved therapies for dry-AMD, which accounts for approximately 90% of all age-related macular degeneration
cases, and is the leading cause of blindness in people over the age of 60.
lead cell delivery clinical product, based on its proprietary HyStem® technology, is Renevia®,
a potential treatment for facial lipoatrophy. “Lipoatrophy” means the loss of fat tissue, which can be caused by several
factors, including trauma, aging, or drug side effects, such as those that cause HIV-associated lipoatrophy. BioTime is also developing
HyStem® for the sustained delivery of therapeutic drugs and targeted cells to specific areas of the body.
2017, BioTime formed AgeX Therapeutics, Inc. (“AgeX”) to
continue development of early-stage programs focusing on development of regenerative medicine
technologies targeting the diseases of aging and metabolic disorders. AgeX’s initial programs focus on utilizing
brown adipose tissue (“brown fat”) in targeting diabetes, obesity, and heart disease; and induced tissue regeneration
(“iTR”) in utilizing the human body’s own abilities to scarlessly regenerate tissues damaged from age or trauma.
AgeX may also pursue other early-stage programs.
August 17, 2017, AgeX completed an asset acquisition and stock sale pursuant to which it received certain assets from BioTime
for use in its research and development programs and raised $10.0 million in cash from investors to finance its operations. This
capitalization of AgeX has allowed BioTime to
focus its resources on its clinical programs in its core therapeutic sectors. As of March
31, 2018, BioTime owned approximately 85% of the issued and outstanding shares of AgeX common stock (see Note 10).
is also enabling early-stage programs in other new technologies through its own research programs as well as through other subsidiaries
also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (“Asterias”)
and OncoCyte Corporation (“OncoCyte”), which BioTime founded and, until recently, were majority-owned and consolidated
subsidiaries. Asterias (NYSE American: AST) is presently focused on advancing three clinical-stage programs that have the potential
to address areas of very high unmet medical needs in the fields of neurology (spinal cord injury) and oncology (Acute Myeloid
Leukemia and lung cancer). OncoCyte (NYSE American: OCX) is developing confirmatory diagnostic tests for lung cancer, breast cancer,
and bladder cancer utilizing novel liquid biopsy technology.
on February 17, 2017, BioTime deconsolidated OncoCyte’s financial statements and results of operations from BioTime
(the “OncoCyte Deconsolidation”) (see Notes 3 and 4). Beginning on May 13, 2016, BioTime also deconsolidated
Asterias’ financial statements and results of operations from BioTime (the “Asterias Deconsolidation”) (see
Notes 3 and 5).